rs11192230 SORCS3 reduced expression in adrenal gland
Upload your raw genetic data once, we'll show you which variants you carry and what the research says.
Key takeaways
- rs11192230 reduces SORCS3 expression in adrenal gland and artery tibial tissue
- The GWAS links the variant to neuropsychiatric disorders with a strong effect (p=3e-11)
- GTEx shows reduced expression in these tissues only
Key takeaways
- rs11192230 reduces SORCS3 expression in adrenal gland and artery tibial tissue
- The GWAS links the variant to neuropsychiatric disorders with a strong effect (p=3e-11)
- GTEx shows reduced expression in these tissues only
What the research says The GWAS Catalog links rs11192230 to neuropsychiatric disorders with a reported effect size of 6.65 p=3e-11 in about 728 thousand individuals risk allele A [PMID 33479212].
Reported associations
- Neuropsychiatric disorders: the variant is associated with a reported effect size of 6.65 p=3e-11 in about 728 thousand individuals risk allele A [PMID 33479212].
Evidence quality The supplied studies do not report a direct trait association for this variant; the rsid appears via GWAS Catalog. The evidence is limited to one GWAS with large sample but not replicated.
Tissue-specific expression effects
- SORCS3 reduced expression in adrenal gland, artery tibial GTEx Portal
No lifestyle considerations on file for this variant.
Frequently asked questions
What does rs11192230 do?
It lowers SORCS3 levels in the adrenal gland and artery tibial tissue.
Is this variant linked to any disease?
The GWAS shows an association with neuropsychiatric disorders but it is not a diagnostic test.
Can I change my expression of SORCS3?
No, the SNP only affects gene activity and does not allow direct changes.